PRECIGEN, INC. Restricted Cash and Cash Equivalents
PRECIGEN, INC. (PGEN) had Restricted Cash and Cash Equivalents of $0 as of 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2019-11-12
- 2019-09-30: Restricted Cash and Cash Equivalents $0.00.
- 2019-06-30: Restricted Cash and Cash Equivalents $0.00.
- 2019-03-31: Restricted Cash and Cash Equivalents $0.00.
- 2018-12-31: Restricted Cash and Cash Equivalents $6.99M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2019-09-30 | $0.00 10-Q · filed 2019-11-12 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-09 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-09 |
| 2018-12-31 | $6.99M 10-Q · filed 2019-11-12 |
| 2018-09-30 | $6.99M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $6.99M 10-Q · filed 2018-08-13 |
| 2018-03-31 | $6.99M 10-Q/A · filed 2018-08-13 |
| 2017-12-31 | $6.99M 10-K · filed 2019-03-01 |
| 2017-09-30 | $6.99M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $6.99M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $6.99M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $6.99M 10-K · filed 2018-03-01 |
| 2016-09-30 | $6.99M 10-Q · filed 2016-11-09 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |